This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity
by Zacks Equity Research
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.
Here's Why Catalent (CTLT) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalent's (CTLT) New Project Completion Expands Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Catalent's (CTLT) New Tie-Up to Provide Better Patient Access
by Zacks Equity Research
Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.
Catalent (CTLT) Down 3.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.
Catalent (CTLT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.
Catalent (CTLT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Biologics segment is likely to have maintained its impressive performance over the past few months, thereby aiding Q2 results.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.
BD (BDX) Hits a New 52-Week High: What's Behind the Rally?
by Zacks Equity Research
A slew of strategic acquisitions are driving the top line for BD (BDX).
Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP
by Zacks Equity Research
Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Catalent (CTLT) to Advance Oral Drug Development With New Launch
by Zacks Equity Research
Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.
PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues
by Zacks Equity Research
PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
AMN Healthcare (AMN) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
AMN Healthcare's (AMN) solid fourth-quarter results are likely to have been boosted by solid segmental performances.
Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid
by Zacks Equity Research
Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.